Does orforglipron, the weight-loss pill, work as well as Ozempic?
Orforglipron works well for blood sugar and weight, but in obesity it is probably less powerful than injectable Ozempic and causes side effects more often. If you want to avoid the injection pen it is a serious option, but discuss it with your doctor, because the direct comparison on weight loss is still missing.
Orforglipron is a pill you take every day that works like Ozempic, but without the injection pen. In people with type 2 diabetes who were already using metformin, orforglipron lowered blood sugar even slightly better than oral semaglutide: the blood sugar marker (HbA1c) fell by 1.71 to 1.91 percentage points, compared with 1.23 to 1.47 percentage points for oral semaglutide. That difference is small but statistically demonstrable.
For weight loss the picture is more nuanced. In people with obesity but without diabetes, orforglipron achieved 9 to 15% weight loss after 36 weeks, which is impressive compared with placebo. But compared with oral semaglutide at a higher dose (25 mg, now available as the successor to Rybelsus), orforglipron falls about 3 percentage points short. That comparison is indirect and was made by Novo Nordisk, the manufacturer of semaglutide itself, so treat it with some caution. A direct study in which both drugs are compared at the same time does not yet exist.
On the point of side effects, orforglipron fares worse. While oral semaglutide causes gastrointestinal complaints in 37 to 45% of users, that figure rises to 58 to 59% with orforglipron. Nine to ten percent of participants stopped because of side effects, compared with 4 to 5% for semaglutide. Heart rate also increased more with orforglipron. The complaints were predominantly mild to moderate, but this is a real difference that counts when you compare the two drugs.
Orforglipron does have one concrete practical advantage. Oral semaglutide must be taken on an empty stomach with a small sip of water, after which you have to wait 30 minutes before eating or drinking anything. Orforglipron has none of those restrictions: simply take it whenever it suits you. That makes adherence to treatment easier for some people.
In summary: orforglipron works at least as well as oral semaglutide for blood sugar, but for weight loss, injectable semaglutide (Ozempic/Wegovy) still appears to be the strongest option. Orforglipron is not a direct replacement for Ozempic in terms of weight effect, but it is a genuine pill with no injection requirement, and for some people that is the deciding factor.
This answer is based on multiple randomised studies, including a large phase 3 study with nearly 1,700 participants over 52 weeks that directly compared orforglipron with oral semaglutide in type 2 diabetes. For the obesity indication, the direct comparison with semaglutide has not yet been carried out in a single study; that comparison is indirect and comes from the manufacturer of semaglutide. Seven randomised studies together confirm the effectiveness and side-effect profile of oral GLP-1 agonists as a class. The quality of evidence for blood sugar control is solid; for the comparison on weight loss in obesity it is weaker because no direct comparative study exists.